Dose Escalation in Partial Response to Escitalopram

Rationale for Dose Escalation

• The Molecular Psychiatry consensus guideline establishes that minimum adequate treatment duration is 4 weeks at the minimum licensed dose before determining treatment failure, supporting the decision to reassess treatment at this point 1, 2, 3

Evidence Supporting the Decision

• Patients who have completed the minimum adequate treatment duration of 4 weeks and demonstrate partial response may benefit from dose escalation, as evidenced by the Molecular Psychiatry consensus guideline 1
• Assessing the degree of improvement at 4 weeks, such as less than 50% improvement, can inform the decision to increase the dose, according to the Molecular Psychiatry guideline 2

Clinical Algorithm

• At 4 weeks with partial response, increasing the dose and continuing for an additional 4 weeks is a recommended approach, with reassessment at 8 weeks total treatment duration, as suggested by the Molecular Psychiatry guideline 1
• If inadequate response is observed at 8 weeks, considering switching to a different mechanism of action or augmentation strategy is advised, based on the Molecular Psychiatry consensus guideline 1, 3